Biopico Systems Inc

Biopico Systems Inc. develops microphysiological systems, specifically the OrganRX™ platform, to advance preclinical drug discovery and biomedical research. Their technology utilizes gravity-driven, unidirectional fluidic recirculation to connect multiple organ models in a multiwell plate format. By engineering physiological fluidic flow and organ microenvironments, the system allows for the co-culture of tissues and the migration of immune cells without requiring artificial membranes. This approach enables researchers to accurately recapitulate human physiology, providing a predictive, high-throughput tool for studying disease pathology, toxicity, and pharmacological responses.

This technology is intended to bridge the gap between traditional in vitro models and clinical outcomes, addressing the limitations of existing preclinical testing in areas such as neurodegenerative diseases, cancer, and age-related health. By providing quantitative, mechanistic data, the OrganRX™ system supports researchers in lead identification, drug optimization, and regulatory-grade decision-making. The company, which is backed by both federal grants and private investment, collaborates with academic and research institutions to validate its platforms for various applications, including senotherapeutics and drug safety assessments.